Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.
Last trade$13.53
Day change-$0.45 (-3.22%)
Day range$13.41 – $14.06
Volume365,138
Market cap$1.09B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.09B
Price / earnings
83.55×
Price / book
1.02×
Price / sales
0.66×
EV / sales
1.61×
EV / EBITDA
11.74×
Profitability
Earnings per share
$0.17
Return on assets
0.37%
Return on equity
1.22%
Dividend yield
0%
Liquidity and leverage
Debt / equity
1.71×
Current ratio
3.62×
Quick ratio
2.21×
Cash ratio
0.77×
Cash flow
Price / cash flow
7.74×
Price / free cash flow
12.67×
Free cash flow
$85.78M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for IART, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$411.18M
$418.76M
$391.92M
$434.93M
$402.06M
$415.61M
$382.65M
$442.65M
Cost of revenue
$201.32M
$199.02M
$174.94M
$214.06M
$195.07M
$206.27M
$188.22M
$193.57M
Gross profit
$209.87M
$219.74M
$216.98M
$220.87M
$206.99M
$209.33M
$194.43M
$249.07M
Selling, general and administrative
$165.31M
$172.44M
$178.24M
$169.27M
$169.05M
$179.89M
$181.5M
$178.52M
Research and development
$21.9M
$24.25M
$23.5M
$24.79M
$22.46M
$27M
$24.73M
$31.21M
Total operating expenses
$190.97M
$200.46M
$205.51M
$197.83M
$195.23M
$722.01M
$209.93M
$213.45M
Operating income
$18.9M
$19.29M
$11.47M
$23.04M
$11.76M
-$512.67M
-$15.5M
$35.63M
Interest expense
-$22.96M
-$22.99M
-$22.47M
-$23.67M
-$22.73M
-$21.04M
-$18.82M
-$18.98M
Income before taxes
$15.66M
$4.74M
-$2.41M
$4.31M
-$6.82M
-$530.95M
-$30.04M
$22.54M
Income taxes
$812K
$262K
$2.21M
$6.01M
-$1.42M
-$46.88M
-$4.74M
$3.11M
Net income
$14.85M
$4.48M
-$4.62M
-$1.7M
-$5.4M
-$484.07M
-$25.29M
$19.44M
Net income attributable to common shareholders
$14.85M
$4.48M
-$4.62M
-$1.7M
-$5.4M
-$484.07M
-$25.29M
$19.44M
EBITDA
$57.96M
$57.42M
$49.9M
$61.47M
$50.28M
$36.38M
$21.69M
$73.22M
Basic earnings per share
$0.19
$0.06
-$0.06
-$0.02
-$0.07
-$6.31
-$0.33
$0.25
Diluted earnings per share
$0.19
$0.06
-$0.06
-$0.02
-$0.07
-$6.31
-$0.33
$0.25
Recent news
Company coverage with links to the original publishers.
The global nerve repair and regeneration market is projected to grow from USD 10.65 billion in 2025 to USD 20.97 billion by 2031, expanding at an 11.96% CAGR. Growth is driven by rising nerve injuries, advances in neurostimulation technologies, and biomaterial innovations. Neurostimulation devices currently dominate with 58.74% market share, while biomaterials are the fastest-growing segment at 14.01% CAGR. High implant costs and cybersecurity risks remain challenges, with Asia-Pacific expected to record the fastest regional growth.
Integra LifeSciences announced that Chief Financial Officer Lea Knight will present at the 2026 UBS Global Healthcare Conference on November 9, 2026. The presentation will be webcast live on the company's investor relations website.
Zacks analysts published research on 16 major stocks on November 2, 2026. Seagate benefits from strong demand and HAMR technology but faces manufacturing risks. Chubb shows resilience but faces pricing pressures and catastrophe risks. Intercontinental Exchange benefits from risk management demand but faces mature market competition. Additional coverage includes ConocoPhillips' low-cost assets, American Electric Power's contracted load growth, and concerns about Smurfit Westrock's freight costs and weak volumes.
Pomerantz LLP is investigating potential securities fraud claims against Integra LifeSciences following significant stock price declines. The company pre-announced disappointing Q3 2026 results on October 2, with a $30.5 million revenue guidance cut due to severe flooding at its Cincinnati facility. Stock fell 21.2% on the announcement and another 8.76% on October 21 when finalized results confirmed worse-than-expected disruptions and a 2.2% organic revenue contraction in its Tissue Reconstruction segment.
Integra reduced its full-year 2026 revenue guidance by $30 million due to severe Cincinnati plant flooding and slower tissue reconstruction business recovery. Despite near-term supply disruptions, the company demonstrated underlying resilience with record operating cash flow of $96 million and strong neurosurgery segment growth of 6.5% organically. Manufacturing capabilities are expected to resume in Q2 2027, with management prioritizing commercial execution and debt reduction.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.